title: BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
abstract: We have analyzed brain and acute leukemia, cytoplasmic (BAALC) gene expression and other genetic markers (ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p = .005), lower complete remission rate after salvage therapy (82% vs 97%; p = .010), and lower 3-year overall (23% vs 58%, p < .001) and relapse-free survival (26% vs 52%, p = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.
authors: Hospital Universitario, Salamanca, Spain. cmsantamaria@usal.es
authors: Carlos
authors: C
authors: Santamaría
authors: María C
authors: MC
authors: Chillón
authors: Ramón
authors: R
authors: García-Sanz
authors: Cristina
authors: C
authors: Pérez
authors: María D
authors: MD
authors: Caballero
authors: María V
authors: MV
authors: Mateos
authors: Fernando
authors: F
authors: Ramos
authors: Alfonso García
authors: AG
authors: de Coca
authors: José M
authors: JM
authors: Alonso
authors: Pilar
authors: P
authors: Giraldo
authors: Teresa
authors: T
authors: Bernal
authors: José A
authors: JA
authors: Queizán
authors: Juan N
authors: JN
authors: Rodríguez
authors: Noemí
authors: N
authors: Puig
authors: Ana
authors: A
authors: Balanzategui
authors: María E
authors: ME
authors: Sarasquete
authors: Miguel
authors: M
authors: Alcoceba
authors: Joaquín
authors: J
authors: Díaz-Mediavilla
authors: Jesús
authors: J
authors: San Miguel
authors: Marcos
authors: M
authors: González
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D000090243:Nucleophosmin; D011237:Predictive Value of Tests; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C442828:BAALC protein, human; D014408:Biomarkers, Tumor; C000716967:NPM1 protein, human; D009363:Neoplasm Proteins; D000090243:Nucleophosmin